A61K 2039/55533
Il-2
Official title: {il-2}
A61K2039/55533 (Il-2) appears on 337 US grants and 506 published applications in this corpus.
Search patents in A61K- Granted patents
- 337
- Published applications
- 506
- Assignees
- 178
- Inventors
- 585
- Latest grant
- 18 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 1 | 0 |
| 1990 | 1 | 0 |
| 1991 | 1 | 0 |
| 1992 | 3 | 0 |
| 1993 | 1 | 0 |
| 1994 | 1 | 0 |
| 1995 | 1 | 0 |
| 1996 | 1 | 0 |
| 1997 | 2 | 0 |
| 1998 | 2 | 0 |
| 1999 | 1 | 0 |
| 2000 | 3 | 0 |
| 2001 | 4 | 5 |
| 2002 | 2 | 8 |
| 2003 | 1 | 14 |
| 2004 | 2 | 11 |
| 2005 | 3 | 10 |
| 2006 | 4 | 11 |
| 2007 | 4 | 9 |
| 2008 | 3 | 9 |
| 2009 | 3 | 14 |
| 2010 | 5 | 10 |
| 2011 | 7 | 8 |
| 2012 | 3 | 7 |
| 2013 | 8 | 7 |
| 2014 | 5 | 8 |
| 2015 | 8 | 11 |
| 2016 | 4 | 8 |
| 2017 | 7 | 19 |
| 2018 | 7 | 26 |
| 2019 | 20 | 33 |
| 2020 | 56 | 73 |
| 2021 | 65 | 64 |
| 2022 | 28 | 45 |
| 2023 | 14 | 36 |
| 2024 | 22 | 22 |
| 2025 | 14 | 23 |
| 2026 | 20 | 15 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Treatment using cytokine encoding RNA18 Aug 2026US 12,708,643 B2BioNTech SE
- Combination therapy using a chimeric antigen receptor16 Jun 2026US 12,653,850 B2Novartis AG
- Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy16 Jun 2026US 12,655,389 B2Iovance Biotherapeutics, Inc.
- Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy9 Jun 2026US 12,648,962 B2Iovance Biotherapeutics, Inc.
- Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy2 Jun 2026US 12,642,816 B2Iovance Biotherapeutics, Inc.
- Hiv immunogenic polypeptides and vaccines and uses thereof24 Sep 2026US 2026/0284175 A1Gilead Sciences, Inc.
- Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy17 Sep 2026US 2026/0272985 A1Iovance Biotherapeutics, Inc.
- Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy17 Sep 2026US 2026/0272986 A1Iovance Biotherapeutics, Inc.
- Dual-germline antibody engager hiv-1 envelope chimeric immunogens27 Aug 2026US 2026/0248907 A1The United States of America, as represented by the Secretary, Department of Health and Human Services
- Methods for Treating HPV16-Associated Cancers20 Aug 2026US 2026/0240979 A1Cue Biopharma, Inc.
Most cited
By later US patents
- Adenovirus vector with multiple expression cassettes110US 6,544,780 B1GenPhar, Inc. · 2003
- Artificial antigen presenting cells and uses therefor105US 7,754,482 B2The Trustees of the University of Pennsylvania · 2010
- Controlled-release formulations of interleukin-294US 5,102,872 ACetus Corporation · 1992
- Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response90US 6,797,276 B1The United States of America as represented by the Secretary of the Army · 2004
- Compositions and methods for identifying antigens which elicit an immune response89US 6,500,641 B1Wake Forest University School of Medicine · 2002